Comparison of phenotypic markers and neural differentiation potential of multipotent adult progenitor cells and mesenchymal stem cells.

AIM To compare the phenotypic and neural differentiation potential of human bone marrow derived multipotent adult progenitor cells (MAPC) and mesenchymal stem cells (MSC). METHODS Cultures of MAPC and MSC were established in parallel from same samples of human bone marrow (n = 5). Both stem cell types were evaluated for expression of pluripotency markers including Oct-4 and Nanog by immunocytochemistry and reverse-transcription polymerase chain reaction (RT-PCR) and expression of standard mesenchymal markers including CD14, CD34, CD44, CD45, CD73, CD90, CD105 and human leukocyte antigen (HLA)-ABC by flow cytometry. After treatment with neural induction medium both MAPC and MSC were evaluated for expression of neural proteins [neuronal filament-200 (NF-200) and glial fibrillar acidic protein (GFAP)] by immunocytochemistry and Western blotting and neural genes [NF-200, GFAP, Tau, microtubule-associated protein (MAP)-1B, MAP-2, neuron-specific enolase (NSE) and oligodendrocyte-1 (Olig-1)] by quantitative real-time-PCR. RESULTS MAPC had small trigonal shaped while MSC had elongated spindle-shaped morphology. The MAPC expressed Oct-4 and Nanog both at gene and protein levels, whereas MSC were negative for these pluripotent markers. MAPC were negative for HLA-ABC while MSC had high expression of HLA-ABC. In addition, MAPC as compared to MSC had significantly lower expression of CD44 (36.56% ± 1.92% vs 98.23% ± 0.51%), CD73 (15.11% ± 2.24% vs 98.53% ± 2.22%) and CD105 (13.81% ± 3.82% vs 95.12% ± 5.65%) (P < 0.001, for all) MAPC cultures compared to MSC cultures treated with neural induction medium had significantly higher fold change expression of NF-200 (0.64), GFAP (0.52), Tau (0.59), MAP-2 (0.72), Olig-1 (0.18) and NSE (0.29) proteins (P < 0.01 for Olig-1 and P < 0.001 for rest) as well as higher fold change expression of genes of NF-200 (1.34), GFAP (1.12), Tau (1.08), MAP-1B (0.92), MAP-2 (1.14) and NSE (0.4) (P < 0.001 for all). CONCLUSION MAPC can be differentially characterized from MSC as Oct-4 and Nanog positive stem cells with no expression of HLA-ABC and low expression of mesenchymal markers CD44, CD73 and CD105 and when compared to MSC they possess greater predilection for differentiation into neuro-ectodermal lineage.

[1]  P. Schiller,et al.  In vitro and in vivo interactions between glioma and marrow-isolated adult multilineage inducible (MIAMI) cells , 2012, Brain Research.

[2]  Zhong-chao Han,et al.  Identification, characterization and biological significance of very small embryonic-like stem cells (VSELs) in regenerative medicine. , 2012, Histology and histopathology.

[3]  F. Roviello,et al.  Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. , 2011, Stem cells and development.

[4]  K. Bae,et al.  Neuron-Like Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells , 2011, Yonsei medical journal.

[5]  C. Verfaillie,et al.  Multipotent adult progenitor cells. , 2011, Best practice & research. Clinical haematology.

[6]  K. Horn,et al.  Multipotent Adult Progenitor Cells Prevent Macrophage-Mediated Axonal Dieback and Promote Regrowth after Spinal Cord Injury , 2011, The Journal of Neuroscience.

[7]  Shinil K. Shah,et al.  Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes , 2010, Experimental Neurology.

[8]  A. Zapata,et al.  Mesenchymal stem cells: biological properties and clinical applications , 2010, Expert opinion on biological therapy.

[9]  N. Nardi,et al.  Biology and applications of Mesenchymal Stem Cells , 2010, Science progress.

[10]  A. Inutsuka,et al.  Unique multipotent cells in adult human mesenchymal cell populations , 2010, Proceedings of the National Academy of Sciences.

[11]  S. Giannotti,et al.  Constitutive Expression of Pluripotency-Associated Genes in Mesodermal Progenitor Cells (MPCs) , 2010, PloS one.

[12]  M. Hoogduijn,et al.  Embryonic Stem Cell Marker Expression Pattern in Human Mesenchymal Stem Cells Derived from Bone Marrow, Adipose Tissue, Heart and Dermis , 2009, Stem Cell Reviews and Reports.

[13]  T. Klingebiel,et al.  Adult stem cells as an alternative source of multipotential (pluripotential) cells in regenerative medicine. , 2009, Current Stem Cell Research & Therapy.

[14]  K. Safranow,et al.  Clinical Evidence That Very Small Embryonic-Like Stem Cells Are Mobilized Into Peripheral Blood in Patients After Stroke , 2009, Stroke.

[15]  C. Schneider,et al.  Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). , 2007, Blood.

[16]  J. L. Cortés,et al.  The low rate of HLA class I molecules on the human embryonic stem cell line HS293 is associated with the APM components' expression level , 2007, Cell biology international.

[17]  M. Richard,et al.  Oct‐4, Rex‐1, and Gata‐4 expression in human MSC increase the differentiation efficiency but not hTERT expression , 2007, Journal of cellular biochemistry.

[18]  A. Luttun,et al.  In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells , 2006 .

[19]  J. Chan,et al.  Human First‐Trimester Fetal MSC Express Pluripotency Markers and Grow Faster and Have Longer Telomeres Than Adult MSC , 2007, Stem cells.

[20]  R. Mays,et al.  Development of adult pluripotent stem cell therapies for ischemic injury and disease , 2007, Expert opinion on biological therapy.

[21]  K. Then,et al.  Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. , 2007, Cytotherapy.

[22]  D J Prockop,et al.  Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.